Results 71 to 80 of about 23,498 (195)
European Journal of Neurology, Volume 33, Issue 5, May 2026.This study combined clinical, demographic, and MRI data from 224 multiple sclerosis (MS) patients using an explainable hybrid deep learning model to assess the prevalence of Mild and Major Neurocognitive Disorders and predict future cognitive decline. The model showed high accuracy (AUC = 0.89) and low uncertainty, identifying cortical and frontal lobe
Loredana Storelli +7 more
wiley +1 more source
Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]
, 2018 Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core +1 more source
Why Is MS a More Frequent Complication of EBV Infection in Females?
Immunological Reviews, Volume 339, Issue 1, May 2026.ABSTRACT Multiple sclerosis (MS) is a T helper (Th) cell‐mediated disease that targets central nervous system (CNS) white matter. This disease affects three times more females than males. For many years, the etiology of MS was not well understood and the exact nature of the autoimmune reaction was speculative.
Shannon E. Dunn +2 more
wiley +1 more source
Anti-α4 Antibody Treatment Blocks Virus Traffic to the Brain and Gut Early, and Stabilizes CNS Injury Late in Infection [PDF]
, 2014 Four SIV-infected monkeys with high plasma virus and CNS injury were treated with an anti-α4 blocking antibody (natalizumab) once a week for three weeks beginning on 28 days post-infection (late).
Autissier, Patrick +9 more
core +3 more sources
Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013
Neurología, 2015 Resumen: Introducción: Natalizumab es un tratamiento que ha demostrado ser muy eficaz en los ensayos clínicos y muy efectivo en la práctica clínica en los pacientes con esclerosis múltiple recurrente-remitente, en cuanto a la reducción del número de ...
O. Fernández +13 more
doaj +1 more source
Network Localization of Fatigue in Multiple Sclerosis
Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 676-687, April 2026.ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo +12 more
wiley +1 more source
Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss
Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 736-746, April 2026.ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund +3 more
wiley +1 more source
Factors that Lead to the Immunotherapy Gap in Multiple Sclerosis Testing [PDF]
, 2013 Multiple sclerosis is a disease that affects the central nervous system. Most doctors and scientists believe that it is an autoimmune disease.
Solai, Karthika
core +1 more source
Advanced Healthcare Materials, Volume 15, Issue 15, 17 April 2026.The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang +13 more
wiley +1 more source
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. [PDF]
, 2013 ObjectiveEtrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC).
Baumgart, Daniel C +16 more
core